Form 4 for KURA Kura Oncology, Inc.
Accepted 2025-09-09 00:00:00 ET · period of report 2025-09-08 · accession 0001415889-25-023974 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-09 | 2025-09-08 | KURA | WILSON TROY EDWARD | Pres, CEO, Dir | P - Purchase | $8.20 | +50.0K | 101.0K | +98% | +$410.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-08 | P | A | 50,000 | $8.20 | 100,968 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $8.135 to $8.24. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakesto provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |